A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

NCT ID: NCT04515849

Last Updated: 2025-01-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 248 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-31
• Study Completion Date: 2022-03-08

Brief Summary

A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

Detailed Description

A Phase 2b randomised, double-blind, placebo-controlled and open-label active comparator study to evaluate the effect of Cotadutide at 100, 300 or 600 micrograms in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.

The study plans to randomise approximately 225 subjects. Subjects will be randomised to receive double-blind Cotadutide or placebo at 100, 300 or 600 micrograms once daily for 26 weeks, or open-label semaglutide at 1.0 miligrams once a week for 26 weeks. Japanese participants will not be randomised to the semaglutide arm.

Conditions

Type 2 Diabetes Mellitus; Chronic Kidney Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Cotadutide 100 micrograms

Cotadutide 100 micrograms administered subcutaneously

Group Type: EXPERIMENTAL

Cotadutide 100 micrograms

Intervention Type: DRUG

Cotadutide 100 micrograms administered subcutaneously

Cotadutide 300 micrograms

Cotadutide 300 micrograms administered subcutaneously

Group Type: EXPERIMENTAL

Cotadutide 300 micrograms

Intervention Type: DRUG

Cotadutide 300 micrograms administered subcutaneously

Cotadutide 600 micrograms

Cotadutide 600 micrograms administered subcutaneously

Group Type: EXPERIMENTAL

Cotadutide 600 micrograms

Intervention Type: DRUG

Cotadutide 600 micrograms administered subcutaneously

Placebo

Placebo administered subcutaneously

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo administered subcutaneously

Semaglutide

Semaglutide 1.0 miligrams administered subcutaneously

Group Type: ACTIVE_COMPARATOR

Semaglutide

Intervention Type: DRUG

Semaglutide 1.0 miligrams administered subcutaneously

Interventions

Cotadutide 100 micrograms

Cotadutide 100 micrograms administered subcutaneously

Intervention Type: DRUG

Cotadutide 300 micrograms

Cotadutide 300 micrograms administered subcutaneously

Intervention Type: DRUG

Cotadutide 600 micrograms

Cotadutide 600 micrograms administered subcutaneously

Intervention Type: DRUG

Semaglutide

Semaglutide 1.0 miligrams administered subcutaneously

Intervention Type: DRUG

Placebo

Placebo administered subcutaneously

Intervention Type: DRUG

Other Intervention Names

MEDI0382; MEDI0382; MEDI0382; Ozempic

Eligibility Criteria

Inclusion Criteria

• Estimated glomerular filtration rate ≥ 20 to < 90 mL/min/1.73 m2 determined at the screening visit or a documented occurrence in medical history at least 3 months prior to randomisation.
• Receiving background standard of care treatment for renal disease and/or T2DM and being treated according to locally recognised guidelines, as appropriate.
• Receiving optimised and stable treatment with an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin II receptor antagonist for ≥ 3 months at screening at the maximum tolerated dose (MTD) unless contraindicated, not tolerated, or in the opinion of the investigator, not practically available or suitable.
• Micro- or macroalbuminuria as defined by UACR > 50 mg/g or 5.7 mg/mmol.
• Diagnosed with T2DM with glucose control managed with any insulin and/or any oral therapy combination including metformin, SGLT2 inhibitor, thiazolidinedione, or acarbose where no major dose changes (eg, > 50% increase in dose) have occurred within the 4 weeks prior to the start of the run-in period. Participants taking sulfonylureas or glitinides may be randomised following a 4-week washout period of the sulfonylurea/glitinide.
• Haemoglobin A1c range of 6.5 % to 12.5% (inclusive) at screening
• Body mass index > 25 kg/m2 at screening or > 23 kg/m2 for participants enrolled in Japan

Exclusion Criteria

• History or presence of significant medical or psychological conditions, including significant abnormalities in laboratory parameters or vital signs including ECG, which in the opinion of the investigator, would compromise the participant's safety or successful participation in the study.
• Receiving renal replacement therapy or expected to require it within 6 months of being randomised
• Renal transplant or on the waiting list for renal transplantation
• Received a GLP-1 analogue-containing preparation within the last 30 days or 5 half-lives of the drug, if known (whichever is longer), at the time of Visit 2
• Received any of the following medications within the specified time frame prior to the start of the study (Visit 2):

1. Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 3 days prior to the start of the run-in period (Visit 2)

2. Paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)

3. Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000 mg and within the last 3 days prior to the start of the run-in period (Visit 2)

• Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives of the drug, if known (whichever is longer)
• Participants with a known severe allergy/hypersensitivity to any of the proposed study interventions or excipients of the product
• Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss) or recent episodes of severe hypoglycaemia
• Type 1 diabetes mellitus (T1DM), history of diabetic ketoacidosis, or clinical suspicion of T1DM
• Participants with recent acute or subacute renal function deterioration
• Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data
• History of acute or chronic pancreatitis
• Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results:

1. Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN)

2. Alanine transaminase (ALT) ≥ 3 × ULN

3. Total bilirubin ≥ 2 × ULN

• Poorly controlled hypertension defined as:

1. Systolic BP > 180 mm Hg

2. Diastolic BP ≥ 90 mm Hg after 10 minutes of seated rest and confirmed by repeated measurement at screening. Participants who fail BP screening criteria may be considered for 24-hour ambulatory BP monitoring at the discretion of the investigator. Participants who maintain a mean 24-hour systolic BP ≤ 180 or diastolic BP < 90 mm Hg with a preserved nocturnal dip of > 15% will be considered eligible

• Unstable angina pectoris, myocardial infarction, transient ischemic attack or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening
• Decompensated heart failure or hospitalisation for heart failure in the 3 months prior to screening or symptoms consistent with New York Heart Association heart failure Class III/IV
• Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
• History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Box Hill, , Australia

Research Site

Elizabeth Vale, , Australia

Research Site

Fitzroy, , Australia

Research Site

Heidelberg, , Australia

Research Site

Melbourne, , Australia

Research Site

Merewether, , Australia

Research Site

Oaklands Park, , Australia

Research Site

Wollongong, , Australia

Research Site

Woolloongabba, , Australia

Research Site

Vancouver, British Columbia, Canada

Research Site

Barrie, Ontario, Canada

Research Site

Brampton, Ontario, Canada

Research Site

Concord, Ontario, Canada

Research Site

Etobicoke, Ontario, Canada

Research Site

Oakville, Ontario, Canada

Research Site

Oshawa, Ontario, Canada

Research Site

Ottawa, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Waterloo, Ontario, Canada

Research Site

Laval, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Dortmund, , Germany

Research Site

Düsseldorf, , Germany

Research Site

Essen, , Germany

Research Site

Kassel, , Germany

Research Site

Ludwigshafen, , Germany

Research Site

Magdeburg, , Germany

Research Site

Mainz, , Germany

Research Site

München, , Germany

Research Site

Münster, , Germany

Research Site

Münster, , Germany

Research Site

Riesa, , Germany

Research Site

Sankt Ingbert, , Germany

Research Site

Arakawa-ku, , Japan

Research Site

Chitose-shi, , Japan

Research Site

Fujisawa-shi, , Japan

Research Site

Kamakura-shi, , Japan

Research Site

Obihiro-shi, , Japan

Research Site

Sapporo, , Japan

Research Site

Shinjyuku-ku, , Japan

Research Site

Auckland, , New Zealand

Research Site

Auckland, , New Zealand

Research Site

Christchurch, , New Zealand

Research Site

Grafton, , New Zealand

Research Site

Havelock North, , New Zealand

Research Site

New Plymouth, , New Zealand

Research Site

Tauranga, , New Zealand

Research Site

Wellington, , New Zealand

Research Site

Bialystok, , Poland

Research Site

Grodzisk Mazowiecki, , Poland

Research Site

Katowice, , Poland

Research Site

Krakow, , Poland

Research Site

Krakow, , Poland

Research Site

Krakow, , Poland

Research Site

Lublin, , Poland

Research Site

Poznan, , Poland

Research Site

Skierniewice, , Poland

Research Site

Warsaw, , Poland

Research Site

Warsaw, , Poland

Research Site

Warsaw, , Poland

Research Site

Wierzchosławice, , Poland

Research Site

A Coruña, , Spain

Research Site

Barcelona, , Spain

Research Site

Córdoba, , Spain

Research Site

L'Hospitalet de Llobregat, , Spain

Research Site

Lleida, , Spain

Research Site

Madrid, , Spain

Research Site

Majadahonda, , Spain

Research Site

Málaga, , Spain

Research Site

Palma, , Spain

Research Site

Palma de Mallorca, , Spain

Research Site

Pozuelo de Alarcón, , Spain

Research Site

Seville, , Spain

Research Site

Seville, , Spain

Research Site

Valencia, , Spain

Research Site

Vitoria-Gasteiz, , Spain

Research Site

Dundee, , United Kingdom

Research Site

Liverpool, , United Kingdom

Research Site

London, , United Kingdom

Countries

Australia; Canada; Germany; Japan; New Zealand; Poland; Spain; United Kingdom

References

Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, Sanchez J, Chang YT, Yu H, Parkinson J, Khan A, Chung HS, Hess S, Dumas R, Duck T, Jolly S, Elliott TG, Baker J, Lecube A, Derwahl KM, Scott R, Morales C, Peters C, Goldenberg R, Parker VER, Heerspink HJL; study investigators. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024 Dec;106(6):1170-1180. doi: 10.1016/j.kint.2024.08.023. Epub 2024 Aug 31.

Reference Type: RESULT

PMID: 39218393 (View on PubMed)

Yu H, Parker V, Selvarajah V, Hansen L, Robertson D, Hamren B, Khan A, Parkinson J. Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus. Br J Clin Pharmacol. 2025 Sep;91(9):2672-2683. doi: 10.1002/bcp.70093. Epub 2025 May 9.

Reference Type: DERIVED

PMID: 40344607 (View on PubMed)

Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

Reference Type: DERIVED

PMID: 39963952 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5676C00001&amp;attachmentIdentifier=6145a98b-b652-4fa3-8311-241cc78fbea6&amp;fileName=CRS_synopsis_redacted.pdf&amp;versionIdentifier=

CSR Synopsis

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5676C00001&amp;attachmentIdentifier=bf1fb852-6916-4dbc-b608-5f07c83def73&amp;fileName=CSP_redacted.pdf&amp;versionIdentifier=

CSP Redacted

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5676C00001&amp;attachmentIdentifier=64031a9c-4cab-45ab-8f8d-f2d2427875f3&amp;fileName=SAP_redacted.pdf&amp;versionIdentifier=

SAP redacted

Other Identifiers

2020-000255-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D5676C00001

Identifier Type: -

Identifier Source: org_study_id